ReviewDrugs2018
The Evolution of Lung Transplant Immunosuppression.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review.BMJ open · 2020Pooled it
- Evaluation of Global Immune Biomarkers to Predict Infections in Lung Transplant Recipients.Clinical transplantation · 2026Article
- Risk factors for nontuberculous mycobacteria infection in lung transplant recipients.BMC pulmonary medicine · 2026Article
- Pharmacological pitfalls in inpatient lung transplant care and management of medication risks.Frontiers in pharmacology · 2026Article
- Pediatric diamond-blackfan anemia after hematopoietic stem cell transplantation complicated by bronchiolitis obliterans and air-leak syndrome leading to lung transplantation: a case report with multimodal follow-up.Frontiers in immunology · 2026Article
- Gram-negative bacterial colonizations before bilateral lung transplant. The impact of 'targeted' versus 'standard' surgical prophylaxis.BMC infectious diseases · 2024Article
- Readmissions and costs in cadaveric and living-donor lobar lung transplantation: Analysis using a national database.JHLT open · 2023Article
- Role of the Nephrologist in Non-Kidney Solid Organ Transplant (NKSOT).Healthcare (Basel, Switzerland) · 2023Article
- Etiologic characteristics revealed by mNGS-mediated ultra-early and early microbiological identification in airway secretions from lung transplant recipients.Frontiers in immunology · 2023Article
- Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Rescue Everolimus Post Lung Transplantation is Not Associated With an Increased Incidence of CLAD or CLAD-Related Mortality.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Current perspective of immunomodulators for lung transplant.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Medical Complications of Lung Transplantation.Journal of chest surgery · 2022Article
- Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.Korean journal of transplantation · 2022Review
- Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation.Pulmonary therapy · 2022Review
- The effect of early tracheal extubation combined with physical training on pulmonary rehabilitation of patients after lung transplantation: a randomized controlled trial.Journal of thoracic disease · 2022Article
- Review: immunosuppression for the lung transplant patient.Journal of thoracic disease · 2021Review
- Interventional and Surgical Treatments for Pulmonary Arterial Hypertension.Journal of clinical medicine · 2021Review
- Network pharmacology-based analysis of the role of tacrolimus in liver transplantation.Saudi journal of biological sciences · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in immunosuppression have been a key component to the ongoing success of lung transplantation. The demographics of patients receiving a lung transplant have evolved with older, more critically ill patients and those with previously contraindicated indications, now becoming recipients. Despite the lack of new classes of maintenance immunosuppression drugs becoming available, advances have been made in the prescribing of traditional immunosuppressive therapies. Developments in immunosuppressive regimens have seen changes in the route of administration, approaches to monitoring and combinations used. Long-term complications of immunosuppression, such as nephrotoxicity and malignancy can limit the success of lung transplantation, and strategies have evolved in recent years to minimise their long-term impact. Although survival outcomes have been steadily improving, chronic lung allograft dysfunction remains a barrier to long-term success. However, treatments for antibody-mediated rejection are emerging as a potential new therapeutic target to decrease the incidence of chronic lung allograft dysfunction. This article provides an update on the current status of immunosuppression after lung transplantation and reviews the evidence for immunosuppressive regimens and the implications for practice.
Indexed as
Identifiers
29915895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.